CUSIP 799566104 · who reports it, how much, and how much it matters to them
17 of the 720 hedge fund managers we track reported shares of Sana Biotechnology, Inc. (Nasdaq: SANA) on Form 13F for 30 June 2026. Between them they reported USD 94m. The largest position belongs to Ra Capital Management, at USD 65m. The manager with the most riding on it is Crestline Management, where it is 4.9% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Ra Capital Management1 fund on PPLI.com | USD 65m | 0.6% |
| 2 | Marshall Wace LLP84 funds on PPLI.com | USD 10m | 0.0% |
| 3 | Renaissance Technologies13 funds on PPLI.com | USD 4.3m | 0.0% |
| 4 | Crestline Management45 funds on PPLI.com | USD 2.6m | 4.9% |
| 5 | Arrowmark Colorado Holdings24 funds on PPLI.com | USD 2.4m | 0.1% |
| 6 | Millennium Management6 funds on PPLI.com | USD 2.3m | 0.0% |
| 7 | Two Sigma Investments35 funds on PPLI.com | USD 2.2m | 0.0% |
| 8 | POINT72 Asset Management17 funds on PPLI.com | USD 2.1m | 0.0% |
| 9 | Baker Bros. Advisors2 funds on PPLI.com | USD 1.1m | 0.0% |
| 10 | Citadel Advisors32 funds on PPLI.com | USD 563,000 | 0.0% |
| 11 | Tudor Investment Corporation10 funds on PPLI.com | USD 307,000 | 0.0% |
| 12 | Brevan Howard Capital Management39 funds on PPLI.com | USD 183,000 | 0.0% |
| 13 | D. E. Shaw & Co.15 funds on PPLI.com | USD 140,000 | 0.0% |
| 14 | Jain Global1 fund on PPLI.com | USD 118,000 | 0.0% |
| 15 | Squarepoint Ops7 funds on PPLI.com | USD 85,585 | 0.0% |
| 16 | MQS Management2 funds on PPLI.com | USD 43,129 | 0.1% |
| 17 | Walleye Capital8 funds on PPLI.com | USD 34,900 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Crestline Management | USD 2.6m | 4.9% |
| 2 | Ra Capital Management | USD 65m | 0.6% |
| 3 | Arrowmark Colorado Holdings | USD 2.4m | 0.1% |
| 4 | MQS Management | USD 43,129 | 0.1% |
| 5 | Marshall Wace LLP | USD 10m | 0.0% |
| 6 | Renaissance Technologies | USD 4.3m | 0.0% |
| 7 | Baker Bros. Advisors | USD 1.1m | 0.0% |
| 8 | Two Sigma Investments | USD 2.2m | 0.0% |
| 9 | POINT72 Asset Management | USD 2.1m | 0.0% |
| 10 | Millennium Management | USD 2.3m | 0.0% |
Sana Biotechnology, Inc. trades under the symbol SANA on the Nasdaq. Its CUSIP, the code used on Form 13F, is 799566104.
17 of the 720 hedge fund managers PPLI.com tracks reported Sana Biotechnology, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Ra Capital Management (USD 65m), Marshall Wace LLP (USD 10m), Renaissance Technologies (USD 4.3m), Crestline Management (USD 2.6m) and Arrowmark Colorado Holdings (USD 2.4m).
17 managers in our coverage reported it, and between them they run 341 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Crestline Management, where the position was 4.9% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Sana Biotechnology, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.